Tags

, , , , , , ,

***

News & Articles


Psyched Out: Brown’s Marty Keller to Step Down


Grassley Probes Financing of Advocacy Group for Mental Health


Treatment advice focuses on drugs, researchers find


3 Researchers at Harvard Are Named in Subpoena


Senator broadens inquiry into psychiatrist


Drug Maker Told Studies Would Aid It, Papers Say


A Silenced Drug Study Creates An Uproar


Once-secret drug-company records put U on the spot


US to Probe Emory, Nemeroff


US cites Boston psychiatrist in case vs. drug firm


SSRI Pushers under Fire

http://www.psychconflicts.org/

***

***
Family of Taser victim sues NYPD

BY ROCCO PARASCANDOLA | rocco.parascandola@newsday.com
February 26, 2009

NYPD Lt. Michael Pigott gets his mail at his home at in Sayville. Pigott died of a self-inflicted gunshot wound on October 2, 2008. (September 25, 2008)

A grieving mother filed a $10- million lawsuit against the New York Police Department yesterday, then broke down as she recalled how police wouldn’t let her talk to her emotionally troubled son moments before he was stunned with a Taser and fell to his death.

He didn’t deserve none of this,  Olga Negron said.  All he needed was help. That’s all.

Her son, Iman Morales, a 35-year-old psychiatric patient, was killed last Sept. 24 in a standoff with police outside his Bedford-Stuyvesant building.

Morales was atop a metal security gate container, naked and waving a fluorescent light, when Emergency Services Lt. Michael Pigott ordered Officer Nicholas Marchesona to use a Taser on Morales, who fell 10 feet to the sidewalk, striking his head.

Pigott, outside his Sayville home six days later, told Newsday he was  truly sorry for what happened to Mr. Morales.  Two days after that, Pigott committed suicide.

Marchesona has since been promoted to detective.  It’s almost as if he was rewarded,  Morales’ brother, Jesse Hernandez, 21, said yesterday at a news conference to discuss the lawsuit.

http://www.newsday.com/news/local/newyork/ny-nymora266049747feb26,0,5525839.story

***

• Jack Wallace was given high doses of psychotropic medications of Seroquel, Depakote, and Ativan at KVHD per orders of pharmacist Hayes. These three medications in combination surely caused resident to have severe side effects that led to his severe dehydration and near comatose state on Oct. 3, 2006. Dr. Locatell believed that these medications at such high dosages were totally unwarranted. In Wallace’s care plan review note, Hughes wrote that Wallace was hallucinating.

http://www.kvsun.com/articles/2009/02/25/news/doc49a5663ca94f8001116390.txt

***

Indian Pharmaceutical Companies To Use experimental Drugs To 49 Infant Deaths

India 49 babies in India to participate in a major hospital drug pilot scheme, the tragic death. Many big pharmaceutical companies around the world are in India for a variety of new drugs in clinical trials, this incident has given rise to concern, criticized the use of baby test pharmaceutical drugs, have requested the authorities to take action to improve ethical standards in this regard.

These babies have been in the 30 months to die, location is located in Delhi’s All India Institute of Medical Sciences. The center is well-known in India, many as an elite of medical students are trained at the center, but also a lot of the poor and the general public to provide cheap medical services, have always enjoyed a good reputation.

Since since January 2006, a total of 4142 infants in the 42 hospitals to participate in clinical trials, mainly as a new drug for the final stage of testing. In these babies, of which 2728 were less than one year old. Many of these babies to participate in pre-clinical trials have been seriously ill, they test the mortality rate was 1.2 percent ─ ─ significantly lower than that of the hospital for treatment of patients of all mortality, the latter four.

However, the choice of testing the child’s age of low, shocked many Indians, it is feared that more and more profitable pharmaceutical industry might use unethical people to take the short cut. India Union Government’s main political parties Congress Party spokesman said: “This kind of the baby as guinea pigs to test drugs practices must be stopped.”

Rights groups worry that those who visit, like the All India Institute of Medical Sciences which public subsidy for the agency to provide parents, as are poor and often illiterate, so they may not know that test new drugs so that the baby contains consequences.

90 percent are poor drug test

In the medical profession, the general principles of human trials is that patients fully understand the purpose of testing and possible risks to agree to participate in the trial after. At this point, patients in Western countries are quite cautious. In the United States, only 3 percent of cancer patients willing to participate in clinical trials of new drugs. India 90% of the test drug were poor, most of them no culture, it is difficult to understand the risks.

India has become an international pharmaceutical companies outsourcing clinical trials of the major countries, and this is mainly due to India’s population and diverse gene pool complex, as well as low-cost do such tests. It is predicted that by 2010, India’s human clinical trials will be the proceeds of one billion pounds in the industry.

India’s tests adequate object. India has more than one billion population, from the ethnic point of view, India has a white, yellow and black, is ideal for a large gene pool for drug testing.

India is also the type of illness in patients with Europe and the United States and other countries are very similar, only there are 32 million people with diabetes. Many people because of poverty have not eaten any medication to treat their disease, which would avoid the drug with the old drugs between the mutual interference. More importantly, clinical trials in India, the cost is much lower. According to the Dutch Agricultural Cooperative Bank estimates, clinical trials in India can be R & D costs六成.

A shortage of 30,000 researchers

However, the Government of India Planning Commission, recent studies have shown that the country’s chronic lack of trained researchers. The report found that researchers in the country a shortfall of 3-50000, including the trial investigators, auditors, the incumbent ethics committee and data safety management committee of qualified staff.

Control of the country’s weak infrastructure, responsible for approving the drug test drug control bureau of inadequate staffing.

All India Institute of Medical Sciences is a great reputation in the international institutions, the hospital spokesman said that there is a very important fact that must be pointed out that that is not yet known at present how many of the deceased is the use of infant drug test, and how many are the control group infants.

It is understood that the Indian Health forces Rama Doss, has ordered investigation into the deaths, the investigation will focus on the All India Institute of Medical Sciences 2 by the World Health Organization and the Indian government-funded trial. Test the time being is not clear what therapy.

http://digghealth.com/indian-pharmaceutical-companies-experimental-drugs-49-infant-deaths/

***

My note –

Just about the time I think it couldn’t be any worse – they wouldn’t do that (meaning drug companies) – and here they are in India using a generation of children and poor families as guinea pigs for their drug testing. That does explain a lot but none of it good.

***

***
Kim Manire wrote on Feb 26, 2009 6:28 AM:
There are cases all across the country that this is happeing in. I am in Texas, and the same thing happened to my father-in-law. He was taken over and locked up and medicated, all his assests were taken and used to pay the court appointed  guardians , and their attorneys, the doctors and the nursing homes. The was estates depleted and then the elderly is put on Medicaide, then within only a few weeks they die of dehydration or pneumonia.

Kim Manire wrote on Feb 26, 2009 6:06 AM:
This is what is happening all across the country:
1. Many of our elderly are taken over by courts,
2. Appointed a guardian,in most cases friends of the court,
3. The guardian then isolates the elderly person and then keeps them from family,
4. This upsets the elderly person, and they start voicing their wishes and wants,
5. So then the guardian, and doctors start medicating, the person is then easier to manage for the staff.

http://www.kvsun.com/articles/2009/02/25/news/doc49a5663ca94f8001116390.txt

***

National Coalition Against Domestic Violence

http://www.ncadv.org/resources/FactSheets_294.html

One in every four women will experience domestic violence in her lifetime.1

An estimated 1.3 million women are victims of physical assault by an intimate partner each year.2

85% of domestic violence victims are women.3

Historically, females have been most often victimized by someone they knew.4

Females who are 20-24 years of age are at the greatest risk of nonfatal intimate partner violence.5

Most cases of domestic violence are never reported to the police.

Almost one-third of female homicide victims that are reported in police records are killed by an intimate partner.14

In 70-80% of intimate partner homicides, no matter which partner was killed, the man physically abused the woman before the murder.12

Less than one-fifth of victims reporting an injury from intimate partner violence sought medical treatment following the injury.15

Intimate partner violence results in more than 18.5 million mental health care visits each year.16

http://www.ncadv.org/files/DomesticViolenceFactSheet(National).pdf

The cost of intimate partner violence exceeds $5.8 billion each year, $4.1 billion of which is for direct medical and mental health services.17

Victims of intimate partner violence lost almost 8 million days of paid work because of the violence perpetrated against them by current or former husbands, boyfriends and dates. This loss is the equivalent of more than 32,000 full-time jobs and almost 5.6 million days of household productivity as a result of violence.17

There are 16,800 homicides and $2.2 million (medically treated) injuries due to intimate partner violence annually, which costs $37 billion.18

(from link above)

***

“In order to survive,
we must go where the money is.”
— Steven Sharfstein, M.D., former President of the
American Psychiatric Association, January 2003

http://www.psychconflicts.org/

**

My note –

apparently they’ve found places to force their drugs on populations where our government through our taxpayer dollars pay for every pill that is sold.

Including subjecting our veterans, our women, our children, our elderly and our disabled populations to their hideous distortions of science and good health. There is no health in it.

***

CHARLESTON, W.Va. — Stan and Shirley White’s son Andrew, a Marine reservist, died at home 2 1/2 years after he returned from Iraq. Janette Layne lost her husband, Eric, in similar circumstances after his return from Iraq.

More than a year later, they still don’t know if the medication their loved ones were taking for post-traumatic stress disorder contributed to their deaths.

Andrew White and Eric Layne were taking Seroquel, Klonopin and Paxil, along with prescription painkillers.
Three other West Virginia servicemen have died in their sleep while undergoing PTSD treatment after returning from Iraq.

http://wvgazette.com/News/200902280644

***

About This Website:
Widespread psychiatric drugging of children has become an increasingly contentious issue, with pharma-funded psychiatrists at the center of the controversy… (read more).

PDF Psychiatric Diagnostic Manual Link to Drug Manufacturers
A Financial Vested Interest Harming in the Name of Mental Health Care

American Psychiatric Association – is sponsored by pharmaceuticals

APA Annual Convention Pharma Sponsors:
PDF APA_Program_2000.pdf
PDF APA_Program_2002.pdf
PDF APA_Program_2003.pdf
PDF APA_Program_2005.pdf
PDF APA_Program_2007.pdf

from 2007 –

This policy is intended to
openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments
about the presentation .

The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose .


The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial
services(s) .

The presenter’s name and the company’s name are listed, along with the page number the presenter appears on in this Program Book .

The nature of the presenter’s relationship with the disclosed company is indicated by the following code : consultant or advisory board’,(subscript 1)

full-time employment’, (subscript 2)

research/grant support 3 , (subscript 3)

speakers’ bureau4 , (subscript 4)

stock or other financial options, other financial or business
relationships’ . (subscript 5)

If a number has not been assigned, the presenter has not disclosed the relationship to the company

Presenter  representing – Manufacturer(s)
Gene G . Abel, M.D.
Abel Screening, Inc .
Hagop S . Akiskal, M.D.
Abbott Laboratories, Inc . 5; AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company3′ 5 ; Eli Lilly and
Company3. 5; GlaxoSmithKline1,3,5; Sanofi-Aventisl ,5
Michael H . Allen, M.D.
Abbott Laboratories, Inc . 1 ‘3 ; Alexza MDC’; AstraZeneca Pharmaceuticals LP ,3 ; Bristol-Myers Squibb
Company’ •3; Eli Lilly and Company3 ; Janssen Pharmaceutica Products, LP 3 ; Pfizer Inc . 1,3
Jonathan E . Alpert, M.D.
Abbott Laboratories, Inc 3; Alkermes, Inc 3 ; Aspect Medical Systems3 ; AstraZeneca Pharmaceuticals LP3;
Bristol-Myers Squibb Company3; Cephalon, Inc.3; Cyberonics, Inc3; Eli Lilly and Companyl,3 s; Forest
Laboratories, Inca; GlaxoSmithKline3;Johnson & Johnson3;Johnson and Johnson Pharmaceutical Research
and Development3 ; Lichtwer Pharma GmbH3 ; Lorex Pharmaceut cals3; National Alliance for Research in
Schizophrenia and Depression3; National Institute of Mental Health3 ; Novartis Pharmaceuticals Corporation 3;
Organon Pharmaceuticals Inc3′ 5 ; PamLab’•3; Pfizer Inc . 3 ; Pharmavite'”3 ; Roche Pharmaceuticals 3 ;
Sanofi/Synthelabo3 ; Sanofi-Aventis 3 ; Solvay Pharmaceuticals, Inc.3; Wyeth-Ayerst Laboratories 3
Lori L. Altshuler, M.D.
Abbott Laboratories, Inc . 3 ‘4; AstraZeneca Pharmaceuticals LP 4’5 ; Bristol-Myers Squibb Companyl ,4 ‘5; Eli Lilly
and Company1,4.5 ; Forest Laboratories, Inc . 1 ‘4; GlaxoSmithKline4’5; Pfizer Inc. 1 ‘4 ; Wyeth Pharmaceuticals4
Sonia Ancoli-Israel, Ph .D. Acadia Pharmaceuticals Inc’ ; Cephalon, Inc . 1,5 ; King Pharmaceuticals, Inc . 1,5 ; Merck & Co., Inc .’ ; Neurocrine
Biosciences Inc.1,5 ; Neurogen Corporation’ ; NIH Institute3; Pfizer Inc .’ ,’ ; Sanofi-Aventis 1 ‘5 ; Sepracor, Inc . 1,5;
Takeda Pharmaceuticals America, Inc . 1,5
Raymond F. Anton, M .D. Alkermes, Inc.’ ; AstraZeneca Pharmaceuticals LP’ ; Bristol-Myers Squibb Company3 ; Cephalon, Inc . 1,5 ; Forest
Laboratories, Inc. 1 ‘ 3 ; Ortho-McNeil Pharmaceutical, Inc 3 ; Pfizer Inc. 3
William J . Apfeldorf, M.D. Abbott Laboratories, Inc . 5; AstraZeneca Pharmaceuticals LP 5 ; Eisai Inca ; Eli Lilly and Company ; Forest
Laboratories, Inc. 1,5 ;Janssen Pharmaceutica Products, LP 5; Pfizer Inc . 5; Wyeth Pharmaceuticals 5
Lesley M . Arnold, M.D.
Cypress Bioscience Inc .’,3; Eli Lilly and Companyl ,3’5 ; Forest Laboratories, Inc .’ ; Pfizer Inc. 1,3,5 ; Sanofi-
Aventis 1 A 3; Sepracor, Inc .; Wyeth Pharmaceuticals 1 . 3
Alan Axelson, M.D.
Eli Lilly and Company5; Novartis Pharmaceuticals Corporations ; Shire Pharmaceuticals Group plc .5
Marion A. Becker, Ph.D.
Eli Lilly and Company3
Julian Beezhold, M .B.Ch .B . AstraZeneca Pharmaceuticals LPs ; Bristol-Myers Squibb Company5 ; Eli Lilly and Companys ; Janssen-Cilag5
Bernard D . Beitman, M.D. Bristol-Myers Squibb Company’
Ruth M. Benca, M.D.
GlaxoSmithKline’ ; Neurocrine Biosciences Inc . 1,5; Pfizer Inc . 1,5 ; Sanofi-Aventis’LS; Sepracor, Inc . 1 ‘ 5 ; Takeda
Pharmaceuticals America, Inc. 1,5 ; Wyeth Pharmaceuticals5
Donna S . Bender, Ph.D.
National Institute of Mental Health’
Susan R. Bergeson, M.B.A. Abbott Laboratories, Inc .’

John L. Beyer, M.D. – Avanir Pharmaceuticals’ ; Bristol-Myers Squibb Company3.5; Eisai Inc . 3 ; Elan Pharmaceuticals, Inc .3; Eli Lilly and
Company’ •5; GlaxoSmithKline3,5; Janssen Pharmaceutica Products, LP5 ; Myriad Genetics, Inc .3; Pfizer Inc . 3
Joseph Biederman, M .D.

Abbott Laboratories, Inc . 1 ‘3 ; Bristol-Myers Squibb Companyl’3 ; Cephalon, Inc . 1,3,5 ; Eli Lilly and Companyl ,3 s;
Janssen Pharmaceutica Products, LP 1,3; McNeil Consumer Healthcarel ,3s; National Institute of Child Health
and Human Development3 ; National Institute of Mental Health 3 ; National Institute on Drug Abuse3 ;
Novartis Pharmaceuticals Corporation’ ,3 5; NRP3 ; Ortho-McNeil Pharmaceutical, Inc . 1,3 >5 ; Pfizer Inc. 1,3; Shire
Pharmaceuticals Group plc . 1,3s; Stanley Medical Research Institute 3 ; UCB Pharmals
Adam Bisaga, M .D. – Forest Laboratories, Inc . 5; GlaxoSmithKlinel
Donald W. Black, M .D. – Forest Laboratories, Inc . 1,3,5; Pfizer Inc. 5; Scirex Corporations ; Shire Pharmaceuticals Group plc . 1,2,35
Carlos Blanco Jerez, M .D. – Somaxon Pharmaceuticals 3
Barton J . Blinder, M.D. – Pfizer Inc . 3
Paul B . Bohn, M .D. – Forest Laboratories, Inc 5 ; Pfizer Inc .’ ; Wyeth-Ayerst Laboratories 5
Curley L . Bonds, M.D. – Abbott Laboratories, Inc.’ ; Pfizer Inc .’
Howard E. Book, M .D. – American Psychological Association Press 4
Charles L. Bowden, M.D. – Abbott Laboratories, Inc . 1,3, 5 ; AstraZeneca Pharmaceuticals LP’ ; Bristol-Myers Squibb Company3 ; Elan
Pharmaceuticals, Inc . 3 ; Eli Lilly and Companyl ,3s; GlaxoSmithKline1,3s;Janssen Pharmaceutica Products,
LP1 .35 ;Johnson and Johnson Pharmaceutical Research and Development3 ; National Institute of Mental
Health 3 ; Parke-Davis 3; Pfizer Inc . 5; Stanley Medical Research Institute 3; UCB Pharmal
Kathleen T. Brady, M.D. – Abbott Laboratories, Inc . 1,3s; Alkermes, Inc .’ ; Cephalon, Inc. 1 ; Eli July and Companyhs; Forest Laboratories,
Inc . 1,3,5 ; GlaxoSmithKlinel . 3,5; National Institute on Drug Abuse’ ,’ ; Ovation Pharmaceuticals, Inc . 1 ; Pfizer
Inc . 1,5; Wyeth Pharmaceuti.cals3
Ronald Brenner, M.D. – AstraZeneca Pharmaceuticals LP’ ; Bristol-Myers Squibb Company ; Eli Lilly and Company’
Thomas E. Brown, Ph .D. – American Psychiatric Press 4 ; Cephalon, Inc .1 ; Eli Lilly and Companyh3 ; McNeil Consumer Healthcarel ,3 ;
Novartis Pharmaceuticals Corporation’ ; Shire Pharmaceuticals Group plc . 1,3
Peter F . Buckley, M.D. – Abbott Laboratories, Inc .’ ,’; Alamo Pharmaceuticalsl •5; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-Myers
Squibb Company1,3,5; Eli Lilly and Companyl ,3s; Janssen Pharmaceutica Products, LP1,3,5 ; Merck & Co., Inc.’ ;
National Institute of Mental Health3; Pfizer Inc .1,3 s; Solvay Pharmaceuticals, Inc .3
Stephen E. Buie, M.D. –
Oscar G . Bukstein
Harold L. Burke, Ph .D.
Presenter
Manufacturer(s)
Avanir Pharmaceuticals’ ; Bristol-Myers Squibb Company3.5; Eisai Inc . 3 ; Elan Pharmaceuticals, Inc .3; Eli Lilly and
Company’ •5; GlaxoSmithKline3,5; Janssen Pharmaceutica Products, LP5 ; Myriad Genetics, Inc .3; Pfizer Inc . 3
Abbott Laboratories, Inc . 1 ‘3 ; Bristol-Myers Squibb Companyl’3 ; Cephalon, Inc . 1,3,5 ; Eli Lilly and Companyl ,3 s;
Janssen Pharmaceutica Products, LP 1,3; McNeil Consumer Healthcarel ,3s; National Institute of Child Health
and Human Development3 ; National Institute of Mental Health 3 ; National Institute on Drug Abuse3 ;
Novartis Pharmaceuticals Corporation’ ,3 5; NRP3 ; Ortho-McNeil Pharmaceutical, Inc . 1,3 >5 ; Pfizer Inc. 1,3; Shire
Pharmaceuticals Group plc . 1,3s; Stanley Medical Research Institute 3 ; UCB Pharmals
Forest Laboratories, Inc . 5; GlaxoSmithKlinel
Forest Laboratories, Inc . 1,3,5; Pfizer Inc. 5; Scirex Corporations ; Shire Pharmaceuticals Group plc . 1,2,35,
Somaxon Pharmaceuticals 3
Pfizer Inc . 3
Forest Laboratories, Inc 5 ; Pfizer Inc .’ ; Wyeth-Ayerst Laboratories 5
Abbott Laboratories, Inc.’ ; Pfizer Inc .’
American Psychological Association Press 4
Abbott Laboratories, Inc . 1,3, 5 ; AstraZeneca Pharmaceuticals LP’ ; Bristol-Myers Squibb Company3 ; Elan
Pharmaceuticals, Inc . 3 ; Eli Lilly and Companyl ,3s; GlaxoSmithKline1,3s;Janssen Pharmaceutica Products,
LP1 .35 ;Johnson and Johnson Pharmaceutical Research and Development3 ; National Institute of Mental
Health 3 ; Parke-Davis 3; Pfizer Inc . 5; Stanley Medical Research Institute 3; UCB Pharmal
Abbott Laboratories, Inc . 1,3s; Alkermes, Inc .’ ; Cephalon, Inc. 1 ; Eli July and Companyhs; Forest Laboratories,
Inc . 1,3,5 ; GlaxoSmithKlinel . 3,5; National Institute on Drug Abuse’ ,’ ; Ovation Pharmaceuticals, Inc . 1 ; Pfizer
Inc . 1,5; Wyeth Pharmaceuti.cals3
AstraZeneca Pharmaceuticals LP’ ; Bristol-Myers Squibb Company ; Eli Lilly and Company’
American Psychiatric Press 4 ; Cephalon, Inc .1 ; Eli Lilly and Companyh3 ; McNeil Consumer Healthcarel ,3 ;
Novartis Pharmaceuticals Corporation’ ; Shire Pharmaceuticals Group plc . 1,3
Abbott Laboratories, Inc .’ ,’; Alamo Pharmaceuticalsl •5; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-Myers
Squibb Company1,3,5; Eli Lilly and Companyl ,3s; Janssen Pharmaceutica Products, LP1,3,5 ; Merck & Co., Inc.’ ;
National Institute of Mental Health3; Pfizer Inc .1,3 s; Solvay Pharmaceuticals, Inc .3
Wyeth Pharmaceuticals 5
Cephalon, Inc .’ ; Eli Lilly and Company3 ; Forest Laboratories, Inc .’ ; Novartis Pharmaceuticals Corporations ;
Ortho-McNeil Pharmaceutical, Inc .s ; Sanofi-Aventis3 ; Shire Pharmaceuticals Group plc . 1,3 s
EEG Spectrum International, Inc 2 .6
George Bush, M.D.
Eli Lilly and Company3; Janssen Pharmaceutica Products, LP 5 ; Johnson and Johnson Pharmaceutical
Research and Developments; McNeil Consumer Healthcare3. 5; Novartis Pharmaceuticals Corporations ; Pfizer
Inc . 3 ; Shire Pharmaceuticals Group plc5
Daniel J . Buysse, M .D.
Cephalon, Inc .’ ; Eli Lilly and Company’ ; GlaxoSmithKline’ ; Merck & Co ., Inc . 1 ; Merck, Sharp, and Dohmel ;
Neurocrine Biosciences Inc .1 ; Neurogen Corporation’ ; Pfizer Inc. 1 . 3 ; Respironics, Inc .’ ; Sanofi-Aventisl ,3 ;
Sepracor, Inc .'”3 ; Servier’ ; Takeda Pharmaceuticals America, Inc 1,3
Nancy Byatt, D.O.
AstraZeneca Pharmaceuticals LP3 ; Eli Lilly and Company3
Joseph R. Calabrese, M .D. Abbott Laboratories, Inc . 1,3; AstraZeneca Pharmaceuticals LP 1 .3 ; Bristol-Myers Squibb Company’ ; Eli Lilly
and Companyh 3; G1axoSmithKline 1,3;Janssen Pharmaceutica Products, LP 1 ‘3 ; Merck & Co., Inc.3; Teva
Pharmaceutical Industries Ltd.’
William E . Callahan, Jr.,M.D. Bristol-Myers Squibb Company’ ; Otsuka America Pharmaceutical, Inc .’
William H . Campbell, M.D. Pfizer Inc .’ ; Sanofi-Aventis 5
Joseph Cappelleri
Pfizer Inc 2
Stanley N . Caroff, M .D.
Bristol-Myers Squibb Company3 ; Ortho-McNeil Pharmaceutical, Inca ; Pfizer Inc . 3

William T. Carpenter, M.D.AstraZeneca Pharmaceuticals LP’ ; Bristol-Myers Squibb Company’ ; Cephalon, Inc .’ ; T .illyl ; National Institute
of Mental Health’-3; Solvay Pharmaceuticals, Inc . 1 ; Wyeth Pharmaceuticals’
Diana Carter, M.B .B .S .
GlaxoSmithKline5; Wyeth Pharmaceuticals’
Daniel E . Casey, M .D.
Abbott Laboratories, Inc .”; Bristol-Myers Squibb Company’ ,5;Janssen Pharmaceutica Products, LP 1 ‘5; Pfizer
Inc.”; Solvay Pharmaceuticals, Inc .’; Sumitomo Pharmaceuticals Co ., Ltd1 ; Wyeth Pharmaceuticals’
David A. Casey, M.D.
Abbott Laboratories, Inc .5; Janssen Pharmaceutica Products, LP 5; Pfizer Inc.5
Alfonso Ceccherini-Nelli, M.D. GlaxoSmithKline2
Robert A. Chambers, M .D . Forest Laboratories, Inc .’ ; National Institute on Drug Abuse 3
Kiki D . Chang, M.D.
Abbott Laboratories, Inc . 1 ‘3 ‘3 ; AstraZeneca Pharmaceuticals LP1,3,5 ; Eli T .illy and Company” ;
GlaxoSmithKline 1 ‘ 3 ; T .illy’; Otsuka America Pharmaceutical, Inc . 3; Shire Pharmaceuticals Group plc . 1

Presenter
Josepha A. Cheong, M .D .
Allen Childs, M .D.
Lois W. Choi-Kain, M .D .
Henry Chung, M.D.
Leslie L. Citrome, M.D.
Daniel J . Clauw, M.D.
Anita L. Clayton, M.D.
Emil F . Coccaro, M.D.
Judith A . Cohen
Francesc Colom, Ph .D.
David O. Conant-Norville, M .D.
Daniel F . Connor, M .D.
Ram Cooppan, M.B.Ch .B .
Manufacturer(s)
AstraZeneca Pharmaceuticals LP5
Abbott Laboratories, Inc .’
National Institute of Mental Health 3
National Institute of Mental Health 3; Pfizer Inc .5
Abbott Laboratories, Inc . 5,6 ; AstraZeneca Pharmaceuticals LP 3,5 ; Bristol-Myers Squibb Companyl ,3,6 ; Eli Lilly
and Company1,3,5,6 ; GlaxoSmithKlinet ; Janssen Pharmaceutica Products, LP 3 ; Jazz Pharmaceuticals, Inc .’ ;
Johnson and Johnson Pharmaceutical Research and Development 6 ; Merck & Co., Inc 6 ; Pfizer Inc . 1sss
Cypress Bioscience Inc . 1,6
Bristol-Myers Squibb Companyl ,3 ; Eli Lilly and Companyt,3> 5 ; Forest Laboratories, Inc .3 ; GlaxoSmithKlinel ,3, 5 ;
Neuronetics, Inc.3 ; Pfizer Inc . 1 .3,5 ; Sanofi-Aventis3 ; Vela Pharmaceuticals, Inc.’ ; Wyeth Pharmaceuticalsl ,3, 5
Abbott Laboratories, Inc . 1,3 ; Eli Lilly and Company3 ; Pfizer Inc .’
Department of Health and Human Services 3 ; Guilford Press 4 ; National Institute of Mental Health 3
AstraZeneca Pharmaceuticals LP5; Lilly5 ; Sanofi-Aventis 5
McNeil Consumer Healthcare 5 ; Novartis Pharmaceuticals Corporations
AstraZeneca Pharmaceuticals LP3; Cephalon, Inc . 5 ; Shire Pharmaceuticals Group plc. 5
Bristol-Myers Squibb Company5 ; Eli Lilly and Company5 ; Novartis Pharmaceuticals Corporations; Novo
Nordisk Pharmaceuticals, Inc . 5 ; Pfizer Inc . 5 ; Sanofi-Aventis 5; Takeda Pharmaceuticals America, Inc . 5 ; Wyeth
Pharmaceuticals 5

http://www.psychconflicts.org/pdfs/APA_Program_2007.pdf

This copy of the disclosure of presenters for the American Psychiatric Association convention goes on for pages and pages which shows specifically that every presenter pushing the use of drug therapy is working for and receiving huge amounts of money from the pharmaceutical / drug companies.

And, they are the same ones who have been setting policy about the use of these drugs on populations within the United States that have no recourse to protect themselves from the living hell that these drugs cause for them and from the systematic bullying of the community and social services who force these drugs on them.

***

Regulatory action

On March 23, 2005, the NASD announced total fines of $21.25 million against Citigroup Global Markets, Inc., American Express Financial Advisors and Chase Investment Services regarding suitability and supervisory violations relating to mutual fund sales practices between January 2002 and July 2003. The case against Citigroup involved recommendations and sales of Class B and Class C shares of mutual funds.[43]

On June 6, 2007, the NASD announced more than $15 million in fines and restitution against Citigroup Global Markets, Inc., to settle charges related to misleading documents and inadequate disclosure in retirement seminars and meetings for BellSouth Corp. employees in North Carolina and South Carolina. NASD found that Citigroup did not properly supervise a team of brokers located in Charlotte, N.C., who used misleading sales materials during dozens of seminars and meetings for hundreds of BellSouth employees.[44]

The Terra Securities scandal

In November 2007 it became public that the Citigroup is heavily involved in the Terra Securities scandal, which involved investments by eight municipalities of Norway in various hedge funds in the United States bond market.[45] The funds were sold by Terra Securities ASA to the municipalities, while the products were delivered by Citigroup. Terra Securities ASA filed for bankruptcy November 28, 2007, the day after they received a letter[46] from The Financial Supervisory Authority of Norway announcing withdrawal of permissions to operate. The same letter also stated,  The Supervisory Authority contends that Citigroup’s presentation, as well as the presentation from Terra Securities ASA, appears insufficient and misleading because central elements like information about potential extra payments and the size of these are omitted.

Theft from customer accounts

On August 26, 2008 it was announced that Citigroup agreed to pay nearly $18 million in refunds and fines to settle accusations by California Attorney General Jerry Brown that it wrongly took funds from the accounts of credit card customers. Citigroup would pay $14 million of restitution to roughly 53,000 customers nationwide. A three-year investigation found that Citigroup from 1992 to 2003 used an improper computerized  sweep  feature to move positive balances from card accounts into the bank’s general fund, without telling cardholders.[47]

Brown said in a statement that Citigroup  knowingly stole from its customers, mostly poor people and the recently deceased, when it designed and implemented the sweeps…When a whistleblower uncovered the scam and brought it to his superiors, they buried the information and continued the illegal practice. [47]

The Treasury Department, the Federal Reserve and the FDIC will cover 90% of the losses on its $335-billion portfolio after Citigroup absorbs the first $29 billion in losses.[48]

As the subprime mortgage crisis began to unfold, heavy exposure to toxic mortgages in the forms of Collateralized debt obligation (CDOs), compounded by poor risk management led the company into serious trouble. In early 2007 Citigroup began eliminating about 5 percent of its workforce, in a broad restructuring designed to cut costs and bolster its long underperforming stock.[20] By November 2008, the ongoing crisis hit Citigroup hard and despite federal TARP bailout money, the company announced further cuts.

Political donations

Citigroup is the 16th largest political campaign contributor, out of all organizations, according to the Center for Responsive Politics. Members of the firm have donated over $23,033,490 from 1989-2006, 49% of which went to Democrats and 51% of which went to Republicans.[51] According to Matthew Vadum, a senior editor at the conservative Capital Research Center, Citigroup is also a heavy contributor to left of center political causes.[52]

http://en.wikipedia.org/wiki/Citigroup

***